What has NICE said?
NICE does not recommend everolimus, given with another drug called exemestane, for postmenopausal women with advanced breast cancer that is HER2 negative and hormone-receptor positive, and that has recurred or worsened after treatment with a non-steroidal aromatase inhibitor (another type of anticancer drug).
Why has NICE said this?
NICE looks at how well treatments work, and also at how well they work in relation to how much they cost the NHS. NICE applies special considerations to treatments that can extend the lives of people who are nearing the end of their life. NICE did not recommend everolimus because it does not provide enough benefit to patients to justify its high cost, and did not qualify for special consideration.